General mechanisms of Antiviral resistance

Genetics and Evolution of Infectious Diseases

Volumn , Issue , 2011, Pages 339-362

  Vere Hodge, Anthony ^a   Field, Hugh J ^b  

^a Vere Hodge Antivirals Ltd   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882505124     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-384890-1.00013-3     Document Type: Chapter

References (26)

1. Andrei G., Gammon D.B., Fiten P., De Clercq E., Opdenakker G., Snoeck R., et al. Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice. J. Virol. 2006, 80:9391-9401.
2. Andrei G., Fiten P., Froeyen M., De Clercq E., Opdenakker G., Snoeck R. DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions. Antivir. Ther. 2007, 12:719-732.
3. Bacon T.H., Levin M.J., Leary J.J., Sarisky R.T., Sutton D. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin. Microbiol. Rev. 2003, 16:114-128.
4. Balzarini J. Targeting the glycans of gp120: a novel approach aimed at the Achille heel of HIV. Lancet Infect. Dis. 2005, 5:726-731.
5. Biswas S., Smith C., Field H.J. Detection of HSV-1 variants highly resistant to the helicase-primase inhibitor BAY 57-1293 at high frequency in two of ten recent clinical isolates of HSV-1. J. Antimicrob. Chemother. 2007, 60:274-279.
6. Chen H., Liu X., Li Z., Zhan P., De Clercq E. TSG101: a novel anti-HIV-1 drug target. Curr. Med. Chem. 2010, 17:750-758.
7. Clavel F., Hance A.J. HIV drug resistance. N. Engl. J. Med. 2004, 350:1023-1035.
8. Drake J.W., Holland J.J. Mutation rates among RNA viruses. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:13910-13913.
9. Duan R., de Vries R.D., Osterhaus A.D.M.E., Remeijer L., Verjans G.M.G.M. Acyclovir-resistant corneal HSV-1 isolates from patients with herpetic keratitis. J. Infect. Dis. 2008, 198:659-663.
10. Dutkowski R. Oseltamivir in seasonal influenza: cumulative experience in low- and high-risk patients. J. Antimicrob. Chemother. 2010, 65(Suppl. 2):ii11-ii24.
11. Field H.J., Vere Hodge R.A. Antiviral agents. Encylopedia of Virology 2008, I:142-154. Elsevier, Oxford. third ed.
12. Field H.J., Wildy P. The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice. J. Hyg. 1978, 81:267-277.
13. Hayden F.G. Combinations of antiviral agents for treatment of influenza virus infections. J. Antimicrob. Chemother. Suppl. B 1986, 18:177-183.
14. Holland J., Domingo E. Origin and evolution of viruses. Virus Genes 1998, 16:13-21.
15. Hu Q., Mahmood N., Shattock R.J. High-mannose-specific deglycosylation of HIV-1 gp120 induced by resistance to cyanovirin-N and the impact on antibody neutralization. Virology 2007, 368:145-154.
16. Kinch M.S., Yunus A.S., Lear C., Mao H., Chen H., Fesseha Z., et al. FGI-104: a broad-spectrum small molecule inhibitor of viral infection. Am. J. Transl. Res. 2009, 1:87-98.
17. Kiso M., Mitamura K., Sakai-Tagawa Y., Shiraishi K., Kawakami C., Kimura K., et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004, 364:759-765.
18. Molla A., Korneyeva M., Gao Q., Vasavanonda S., Schipper P.J., Mo H-M., et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 1996, 2:760-766.
19. Okomo-Adhiambo M., Nguyen H.T., Sleeman K., Sheu T.G., Deyde V.M., Garten R.J., et al. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses. Antiviral Res. 2010, 85:381-388.
20. Paris D.S., Harrington J.E. Herpes simplex virus variants resistant to high concentrations of acyclovir exist in clinical isolates. Antimicrob. Agents Chemother. 1982, 22:71-77.
21. Shafer R.W. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin. Microbiol. Rev. 2002, 15:247-277.
22. Smith D.B., Inglis S.C. The mutation rate and variability of eukaryotic viruses: an analytical review. J. Gen. Virol. 1987, 68:2729-2740.
23. Stephenson I., Democratis J., Lackenby A., McNally T., Smith J., Pareek M., et al. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. Clin. Infect. Dis. 2009, 48:389-396.
24. Sukla S., Biswas S., Birkmann A., Lischka P., Zimmermann H., Field H.J. Mismatch primer-based PCR reveals that helicase-primase inhibitor resistance mutations pre-exist in herpes simplex virus type 1 clinical isolates and are not induced during incubation with the inhibitor. J. Antimicrob. Chemother 2010, 65, 1347-1352.
25. Tashiro M., McKimm-Breschkin J.L., Saito T., Klimov A., Macken C., Zambon M., et al. Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996-2007. Antivir. Ther. 2009, 14:751-761.
26. Zhao X., Sullender W.M. In vivo selection of respiratory syncytial viruses resistant to palivizumab. J. Virol. 2005, 79:3962-3968.